Every material Form 8-K TuHURA Biosciences, Inc./NV has filed with the SEC since September 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TuHURA Biosciences borrowed an additional $1.5 million on November 2, 2026, under the revolving credit facility from its April 21, 2026 Loan Agreement with Parkview Holdings One LLC. The facility has a maximum availability of $50 million and matures on April 21, 2031, and the company says it will use the funds for general corporate purposes.
Draw of $1,500,000 received and borrowed on November 2, 2026
Revolving facility with Parkview Holdings One LLC has maximum availability of $50 million
Facility matures April 21, 2031; the Loan Agreement was originally entered into April 21, 2026
Filing notes potential conflicts of interest because the lender is an affiliate of the company's largest stockholder
TuHURA Biosciences borrowed an additional $650,000 on October 9, 2026, under a revolving credit facility with Parkview Holdings One LLC, as disclosed in a Form 8-K filed October 16, 2026. The company said it expects to use the funds for general corporate purposes, and the draw is small relative to the $50 million maximum availability under the facility.
Draw of $650,000 received and borrowed on October 9, 2026
Revolving credit facility under Loan Agreement dated April 21, 2026, with a maximum loan availability of $50 million
Facility matures April 21, 2031; the company expects to use funds for general corporate purposes
Filing notes risks including potential conflicts of interest from the loan with an affiliate of the largest stockholder
TuHURA Biosciences said it borrowed an additional $650,000 on September 21, 2026, under the revolving credit facility it set up with Parkview Holdings One LLC on April 21, 2026. The facility matures on April 21, 2031, and the company expects to use the funds for general corporate purposes. The filing notes the lender is an affiliate of the company's largest stockholder and that the company may need additional capital.
Draw of $650,000 received and borrowed on September 21, 2026
Revolving credit facility with Parkview Holdings One LLC has a maximum loan availability of $50 million
Facility matures on April 21, 2031; funds to be used for general corporate purposes
Filing cites potential conflicts of interest because the lender is an affiliate of the largest stockholder
TuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on September 14, 2026, which it expects to use for general corporate purposes. The facility has a maximum availability of $50 million and matures on April 21, 2031, so the draw adds a small amount of debt against that capacity.
Draw of $650,000 received and borrowed on September 14, 2026 under the revolving credit facility
Loan Agreement with Parkview Holdings One LLC dated April 21, 2026, with maximum loan availability of $50 million
Facility matures April 21, 2031; filing notes lender is an affiliate of the company's largest stockholder
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TuHURA Biosciences, Inc./NV filing is on SEC EDGAR ↗. 8-K briefs of other companies →